LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42140755无 PMCID | 2026-Jul | 0.85 | The study is a Phase III randomized trial in oncology with a drug intervention (iADT), but the primary and only reported efficacy endpoint is safety/toxicity. No time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or associated Kaplan-Meier curves or hazard ratios are presented, making it ineligible for a Kaplan-Meier digitization cohort focused on efficacy. | 无 KM 图 |
| Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial.Drugs疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图。 | PMID 42165988PMC13290787 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42166701无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42167105无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.Lancet Gastroenterol Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42202843无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42214243无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Secukinumab for Giant Cell Arteritis.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42234457无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| HTD1801 in Combination with Metformin for Type 2 Diabetes.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42251702无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.Lancet OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42269655无 PMCID | 2026-Jul | 0.95 | The record is a Phase III randomized controlled trial in oncology with original results, but it does not meet the drug intervention or time-to-event efficacy endpoint criteria. The intervention is a diagnostic imaging agent ([68Ga]Ga-PSMA-11 PET-CT), not a therapeutic drug. The primary endpoints are proportions (clinically significant cancer detection and biopsy avoidance), not time-to-event outcomes like OS or PFS. | 无 KM 图 |
| Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42296979无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.J Geriatr Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42308688无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42309084无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42372741无 PMCID | 2026-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42372743无 PMCID | 2026-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42372745无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42372746无 PMCID | 2026-Jul | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 无 KM 图 |
| Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.Clin Transl Sci入排复审未纳入:The record describes a population pharmacokinetic and exposure-response analysis of favezelimab. While it includes data from a Phase 3 randomized trial, the analysis focuses on objective response rate (ORR) and safety, not on a primary or key secondary time-to-event efficacy endpoint like OS or PFS. There is no mention of Kaplan-Meier estimates, hazard ratios, or other time-to-event analyses. Therefore, it does not meet the required criterion of having a primary/key secondary time-to-event efficacy endpoint. | PMID 42397055PMC13330136 | 2026-Jul | 0.85 | The record describes a population pharmacokinetic and exposure-response analysis of favezelimab. While it includes data from a Phase 3 randomized trial, the analysis focuses on objective response rate (ORR) and safety, not on a primary or key secondary time-to-event efficacy endpoint like OS or PFS. There is no mention of Kaplan-Meier estimates, hazard ratios, or other time-to-event analyses. Therefore, it does not meet the required criterion of having a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |
| Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.JCO Precis OncolAI 判定该论文不进入自动 KM 提取:This is a biomarker development and validation study using data from prior Phase III trials, not a new Phase III RCT itself. | PMID 42418739无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-term safety and efficacy of voclosporin in Asian patients with lupus nephritis: A post hoc analysis of the AURORA 2 trial.Mod Rheumatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41410387无 PMCID | 2026-Jun-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial.Stroke Vasc Neurol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:非 KM 图。 | PMID 41151803PMC13347805 | 2026-Jun-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial.BMJ Open Ophthalmol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 42373197PMC13331159 | 2026-Jun-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42214392无 PMCID | 2026-Jun-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42218899无 PMCID | 2026-Jun-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.J NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42360473无 PMCID | 2026-Jun-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41849227无 PMCID | 2026-Jun-25 | 0.85 | The study is a Phase III randomized trial with a time-to-event efficacy endpoint (GVHD-free, relapse-free survival). However, the intervention compares different graft-versus-host disease prophylaxis regimens (ATG, PTCy, combination) in haploidentical transplantation. The eligibility criteria require a drug-containing intervention (i.e., a drug as the primary experimental agent against a control). While ATG and cyclophosphamide are drugs, the trial's design is more procedural/regimen-focused, and the deterministic review flagged unclear drug intervention evidence. Without explicit confirmation that the trial is testing a specific drug (e.g., a new drug vs. standard) rather than comparing prophylaxis strategies, it does not meet the strict drug-intervention criterion. All other criteria are met, but the drug-intervention criterion cannot be confidently established as true, so is_eligible is false. | 无 KM 图 |
| Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42202479无 PMCID | 2026-Jun-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42206582无 PMCID | 2026-Jun-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42341301无 PMCID | 2026-Jun-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 flow diagram。 | PMID 42033722PMC13110413 | 2026-Jun-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of hydrocolloid dressing for hand-foot skin reaction: J-SUPPORT 1701 APRON trial.Support Care Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。 | PMID 42337018PMC13290941 | 2026-Jun-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.Br J Ophthalmol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41448868PMC13311981 | 2026-Jun-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.Chin Med J (Engl) | PMID 41424028PMC13282095 | 2026-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41980234无 PMCID | 2026-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42217458无 PMCID | 2026-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42225112无 PMCID | 2026-Jun-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prehospital Whole Blood in Traumatic Hemorrhage - A Randomized Controlled Trial.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41841706无 PMCID | 2026-Jun-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41911073无 PMCID | 2026-Jun-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41915772无 PMCID | 2026-Jun-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1 –:CONSORT/入组流程图;Figure 2 -:非 KM 图。 | PMID 41972998PMC13078690 | 2026-Jun-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.Eur J CancerAI 判定该论文不进入自动 KM 提取:The trial is explicitly described as a phase II trial. | PMID 42142431无 PMCID | 2026-Jun-18 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:CONSORT/入组流程图;Figure 3.:CONSORT/入组流程图。 | PMID 42150044PMC13313084 | 2026-Jun-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Unsuppressed Viremia and Lower CD4 Count Associated With Faster Telomere Attrition in African Children With Perinatal Human Immunodeficiency Virus on Long-term Antiretroviral Therapy.J Infect Dis入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41655979PMC13271384 | 2026-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana.Circulation疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3::非 KM 图。 | PMID 41953982PMC13156604 | 2026-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial.J Am Heart Assoc已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。 | PMID 42261967PMC13323578 | 2026-Jun-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.Clin Cancer Res | PMID 41915435PMC13266337 | 2026-Jun-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42242268无 PMCID | 2026-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42250575无 PMCID | 2026-Jun-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.Blood | PMID 41770817PMC13277654 | 2026-Jun-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.J Clin Oncol | PMID 41369677PMC13258094 | 2026-Jun-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.J Clin Oncol已检查 3 张 PubMed Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:AI 判定为 other;FIG 3.:森林图/亚组分析图。 | PMID 41576297PMC13258097 | 2026-Jun-10 | 0.95 | The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it is ineligible because the primary efficacy endpoint is pathologic complete response (pCR), which is a binary outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). No time-to-event analysis, Kaplan-Meier, or hazard ratio for efficacy is indicated in the abstract. | 无 KM 图 |